MTOR and acute myeloid leukemia: Importantly, pharmacological or genetic inhibition of PI3K/AKT/mTOR rescues the aggressive phenotypes induced by ARF6 overexpression, establishing this pathway as a critical mediator of ARF6's oncogenic effects in AML.